PORTLAND, Ore., Feb. 28, 2017 /PRNewswire/ -- This year, the National Psoriasis Foundation (NPF) celebrates 50 years of patient support, advocacy, research funding, education and outreach to the more than 8 million individuals living with psoriasis and psoriatic arthritis. Originally formed in 1966 as The Psoriasis Society of Oregon, and officially becoming the National Psoriasis Foundation in 1967, its mission is focused on driving efforts to cure psoriatic disease and dramatically improving the lives of those affected.

Throughout its first 50 years, NPF has made significant contributions in advancing the research of life-changing treatments that have helped millions of people. From the tar-based procedures and topical creams to the revolutionary biologic treatments that exist today, NPF has always supported innovative approaches to treating psoriasis and psoriatic arthritis. While these achievements are to be celebrated, there is still much work to be done to improve access to treatments and, ultimately, to find a cure.

"We have only scratched the surface of what could be possible in treatingand ultimately curingpsoriasis and psoriatic arthritis. Advancements in psoriatic disease research are happening all the time, and NPF remains committed to funding this research while offering programs and services that support even more patients," said Dr. Colby Evans, M.D., National Psoriasis Foundation board chair. "I am honored to be associated with an organization that has always been at the forefront of driving efforts to find a cure for psoriasis and psoriatic arthritis."

NPF has achieved many milestones over the past 50 years, including securing for the first time ever, line-item funding in a federal budget for skin disease research, successfully lobbying the U.S. Food & Drug Administration for the approval of methotrexate for the treatment of severe psoriasis and opening the world's first support center providing free personalized assistance for people with psoriatic disease. Most recently, members of the NPF Medical Board issued the first paper in the United States that outlines psoriasis treatment targets and goals for individuals and health care providers to work on together to achieve clear skin and ultimately reduce the burden of the disease.

"NPF has been a pioneer in supporting research efforts that have led to the groundbreaking treatments used today," said Randy Beranek, president and CEO of the National Psoriasis Foundation. "During our 50th year, we are excited to recognize the people and milestones that have contributed so much to the psoriatic disease community, and remain committed to supporting research efforts towards finding a cure and dramatically improving the health outcomes of all affected by psoriasis and psoriatic arthritis."

In remaining true to its mission, the theme of the NPF 50th Year Celebration is "Driving Discovery, Creating Community." This allows the Foundation to celebrate the achievements of the past 50 years and to recognize the individuals and milestones that have made significant contributions to the psoriatic disease community. To recognize its 50th year, NPF will be holding events throughout the year, starting with a formal celebration on June 8, 2017, at the Plaza Hotel in New York City, and followed by the National Volunteer Conference and Research Symposium August 4 6, 2017 in Chicago, IL, as well as various TeamNPF events across the country.

Read More

During this year of celebration, NPF is committed to raising $2 million to fund several promising areas of research and programing, specifically early career research. Supporting the NPF 50th year campaign will ensure that researchers studying psoriatic disease will have the resources needed to turn their questions and theories into a cure.

To learn more about the NPF 50th Year Celebration and how to get involved, visit: https://www.psoriasis.org/NPF50th.

Over the last 50 years, the National Psoriasis Foundation (NPF) has become the world's leading nonprofit patient advocacy organization fighting for individuals with psoriasis and psoriatic arthritis. NPF leads this fight by driving efforts for a cure and improving the lives of the more than 8 million Americans affected by this chronic disease. To date, NPF has funded more than $15 million in research grants and fellowships, and to commemorate 50 years, NPF plans to raise an additional $2 million for early scientific career research programs in 2017 alone. Each year, NPF strives to support, educate and advocate on behalf of more individuals living with or caring for someone with the disease than ever before. As part of that effort, NPF established the Patient Navigation Center to offer personalized assistance to everyone with psoriasis or psoriatic arthritis. Join our community today and help drive discovery and create community for all living with psoriatic disease.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/national-psoriasis-foundation-celebrates-50-years-of-patient-support-advocacy-research-education-and-outreach-300414766.html

Excerpt from:

National Psoriasis Foundation Celebrates 50 Years of Patient Support, Advocacy, Research, Education and Outreach - Yahoo Finance

Lina Eliasson,1 Anthony P Bewley,2 Farhan Mughal,3 Karissa M Johnston,4 Andreas Kuznik,5 Chloe Patel,1 Andrew J Lloyd1

1Clinical Outcomes Assessment, ICON Clinical Research UK Ltd, 2Department of Dermatology, Whipps Cross University Hospital, Barts Health National Health Service Trust, London, 3Health Economics Outcomes Research, Celgene Ltd, Uxbridge, UK; 4Epidemiology, ICON Commercialisation and Outcomes, Vancouver, BC, Canada; 5Global Health Economics and Outcomes Research, Celgene Corporation, Summit, NJ, USA

Objective: Treatment options for psoriasis offer trade-offs in terms of efficacy, convenience, and risk of adverse events. We evaluated patients preferences with respect to benefitrisk in the treatment of psoriasis. Methods: A discrete choice experiment was conducted in adults from the UK with moderate-to-severe psoriasis using an orthogonal design with 32 hypothetical choice sets. Participants were randomly assigned to one of two surveys with 16 choice sets. Patients preferences were investigated with respect to the following attributes: reduction in body surface area affected by psoriasis, treatment administration (frequency and mode of delivery), short-term diarrhea or nausea risk, and 10-year risk of developing melanoma or nonmelanoma skin cancer, tuberculosis, or serious infections. A mixed effects logistic regression model generated relative preferences between treatment profiles. Results: Participants (N=292) had a strong preference to avoid increased risk of melanoma or nonmelanoma skin cancer (odds ratio [OR]: 0.44 per 5% increased 10-year risk) and increased risks of tuberculosis and serious infections (both ORs: 0.73 per 5% increased 10-year risk) and preferred once-weekly to twice-daily tablets (OR: 0.76) and weekly (OR: 0.56) or fortnightly (OR: 0.65) injections. Participants preferred avoiding treatments that may cause diarrhea or nausea in the first 2 weeks (OR: 0.87 per 5% increase) and preferred treatments that effectively resolved plaque lesions (OR: 0.93 for each palm area still affected). Conclusion: All attributes were significant predictors of choice. Patients preference research complements clinical trial data by providing insight regarding the relative weight of efficacy, tolerability, and other factors for patients when making treatment choices.

Keywords: benefit, discrete choice experiment, patients preferences, psoriasis, risk, treatment

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Here is the original post:

Evaluation of psoriasis patients' attitudes toward benefitrisk and therapeutic trade-offs in their choice of treatments - Dove Medical Press

Home Skin Health Home remedies to soothe your psoriasis

Psoriasis is a skin disorder that causes the epidermis to become covered in raised, red, itchy plaques that are spotted with white scales. It most commonly occurs on the knees, elbows, and scalp, but may also affect your torso, palms, and the soles of your feet. These plaques are sometimes itchy and painful, and may even crack and bleed, making the condition both uncomfortable and unsightly. While there are medications available to help soothe the symptoms of psoriasis, some may prefer a simpler home remedy. Continue reading to discover some of the most common and effective home remedies for treating psoriasis.

Heavy cream. Use a thick moisturizer or petroleum jelly to lock in moisture to the affected areas. Hydrating your skin with a heavy-duty salve can help relieve the itchiness associated with dry, scaly patches.

Apple cider vinegar. If your scalp is affected by psoriasis, you may be wary of slathering a cream over it for fear of making your hair limp and greasy. So long as the skin of your scalp is not bleeding or cracked, you can rub apple cider vinegar over it to soothe the itch. This is best done before a shower, as once the vinegar dries, you should rinse it out to avoid any further irritation.

Sun. The suns rays can actually help fight psoriasis, so head out into the sunshine for a few minutes daily and get your fill. Be sure to use sunscreen on the areas of your body not affected by the skin disorder to prevent sun damage that may lead to skin cancer.

Epsom salts. Sprinkle some Epsom salts into a warm bath and soak for about 15 minutes. The salts will help rid your body of the silvery scales and soothe any itching. Pat yourself dry after stepping out of the tub and be sure to moisturize in order to lock in all that moisture and keep your skin hydrated.

Oats. An oat bath is also a great way to soothe dry, itchy skin. Mix some ground-up oats into your warm bath water, then relax in the tub and let this natural remedy work its magic. Just as you would after an Epsom salt bath, ensure you moisturize afterward to seal in the hydration.

Meditation and yoga. Stress can exacerbate your condition, so partaking in activities like yoga and meditation to help manage it may also reduce your symptoms. This is especially true for those with psoriatic arthritis, as yoga can help alleviate your joint pain and reduce itchy flare ups.

Aloe Vera. Aloe Vera gel is a go-to to soothe sunburns, but its cooling and anti-inflammatory properties have also been found to ease the symptoms of psoriasis. The gel can help reduce redness and get rid of the irritating itch.

Psoriasis is an irritating condition that leaves your skin sore and itchy, and while there are some medications on the market to help treat it, there are also a few tried and true home remedies to ease your symptoms. Next time you experience a flare-up, try reaching for the apple cider vinegar or Epsom salts to rid yourself of the discomfort, and be sure to moisturize your skin daily.

Related: Psoriasis diet: What foods to eat and what foods to avoid?

Related Reading:

Psoriasis skin inflammation treatments improve heart disease symptoms: Study

Treating psoriasis reduces risk of other ailments: Study

http://www.webmd.com/skin-problems-and-treatments/psoriasis/ss/slideshow-home-remedies-for-psoriasis

Original post:

Home remedies to soothe your psoriasis - Bel Marra Health

In 2013, the Centers for Disease Control and Prevention led a collaborative effort to develop the first-ever public health agenda for psoriasis and psoriatic arthritis. Their agenda was published in the American Journal of Preventative Medicine.

A public health approach to psoriatic diseases will allow scientists to better identify possible environmental contributions, which could potentially help us stop these diseases before they start, Andrew D. Robertson, chief scientific and medical officer for the National Psoriasis Foundation, stated in a post by the Foundation.

Read:Psoriasis Facts And Myths: 5 Things To Know About Misunderstood Immune Disease

Psoriasis is a chronic autoimmune disease that causes patches of red, scaly skin. About 10to 20 percentof people with psoriasis will develop an inflammatory type of arthritis known as psoriatic arthritis, according to the CDC. It causes your joints to become painful, swollen, and warm to the touch.

These are eights signs you may be at risk for psoriatic arthritis:

1. You have psoriasis.The majority of those with psoriatic arthritis developpsoriasis first.

2. Youre overweight.Although research is still growing, there's been findings associating being overweight and having psoriasis and psoriatic arthritis.

3. You have psoriasis in your nails. Of the patients with both psoriasis andpsoriatic arthritis, approximately 80 percenthave nail disease, research published in the Journal of the European Academy of Dermatology and Venerology reports.

4. You were young when diagnosed with psoriasis.Children are more likely than adults to experience the onset of psoriasis andpsoriatic arthritis simultaneously, the National Psoriasis Foundation reports.

5. You have a family member with psoriatic arthritis and you also have psoriasis. Genetic factors are important forpsoriatic arthritis risk, but the research is ongoing regarding exactly which genes are responsible.

6. You have an injury.Physical trauma may be associated with triggeringpsoriatic arthritis among those with psoriasis, astudy concludes.

7. You have had strep throat.Common infections, such as strep throat, may be a trigger forpsoriatic arthritis flare-ups, Healthline reports.

8. You have HIV.Those with the immunodeficiency disorder are more likely to havepsoriatic arthritis. Psoriatic arthritis may precede the detection of HIV infection, according to the American College of Rheumatology.

Although psoriatic arthritis typically occurs in people who have psoriasis, it still can affect those who dont have the disease. Theres currently no cure for psoriatic arthritis, but treatments including nonsteroidal anti-inflammatory drugs, immunosuppressants, and steroid injections, among other inflammation control methods may help to prevent joint pain and disability, according to Mayo Clinic.

See more:Psoriasis Associated with Higher Odds of Having One of 14 Autoimmune Diseases

Psoriasis Treatment: 5 Natural Ways To Alleviate The Skin Disorder At Home

The rest is here:

Psoriatic Arthritis: 8 Signs You May Be At Risk For The Autoimmune Disease - Medical Daily

Psoriasis is a chronic autoimmune condition that causes the rapid build-up of skin cells. This build-up of cells causes scaling on the skins surface.

Inflammation and redness around the scales is fairly common. Typical psoriatic scales are whitish-silver and develop in thick patches. Sometimes, these patches will crack and bleed.

People with psoriasis may find living with the condition challenging.

Here are four tips on how to cope with psoriasis:

1. UPDATING MAKE-UP

Daily cosmetic products could be worsening skin irritation and redness. Clients should look for fragrance-free, hypoallergenic and non-clogging moisturisers to support skin with an extra layer of protection.

Primers will give users a smoother skin surface to work with, and liquid foundation can be easily controlled with any skin type.

As for removing make-up, petroleum-based make-up removers loosen make-up prior to taking it off and can help avoid aggravating sensitive spots.

2. EATING HEALTHY

Controlling diet can be beneficial for individuals with psoriasis as some foods can cause redness and swelling of the skin. An anti-inflammatory diet has proven to help individuals manage plaque psoriasis.

Psoriasis sufferers should eat: Fish, nuts, oils, and colourful fruits and vegetables. Foods to avoid include: Nightshade vegetables, dairy, refined sugar, and red meat.

3. TAKING VITAMINS

Many people with psoriasis find that including vitamins and supplements in their diet help their skin clear.

Omega 3 helps decrease inflammation and powers the immune system through fish oil, vegetable oil, soy, nuts, and seeds.

Vitamin D can be found in salmon, Swiss cheese and sunshine, which helps slow the growth of skin cells.

4. LOWERING STRESS LEVELS

Psychodermatology is a term doctors created, linking emotional stress to skin. Bodies reacting to a mental state can trigger certain hormones to be released, which can cause skin to have negative side effects.

The brain and skin are connected because they are derived from the same cells. When people experience stress in life, quite frequently their skin becomes a reflection of the stresses.

The following can help reduce stress levels: Acupuncture, massage therapy, behavioural therapy, talk therapy, and relaxation training.

Michelle Vernon is a licensed aesthetician who operates the Body Studio Skincare located at 23 Central Plaza, Kingston 10, and Fairview Shopping Centre, Montego Bay. She may be reached at telephone 908-0438 or 684-9800; IG@bodystudioskincare; E-mail: bodystudioskincare@gmail.com; Website: http://www.bodystudioskincare.com.

Read the original:

How to cope with Psoriasis - Jamaica Observer

Everyday Health (blog)

Depression puts psoriasis patients at significantly greater risk of psoriatic arthritis Science Daily Psoriasis is a lifelong disease that is associated with significant cosmetic and physical disability and puts patients at increased risk for many major medical disorders. A multidisciplinary team of researchers at the University of Calgary, Canada ... Can Depression Up Odds for Arthritis Linked to Psoriasis?Everyday Health (blog) Psoriasis Patients Who Suffer From Depression at Higher Risk for Psoriatic ArthritisCDA News Depression raises risk of developing psoriatic arthritisOnMedica Healthcare Today all 5 news articles »

Read the original:

Depression puts psoriasis patients at significantly greater risk of psoriatic arthritis - Science Daily

Depression in people with the chronic inflammatory skin disease psoriasis increases the risk of getting the joint condition known as psoriatic arthritis by about 37 percent, new research indicates.

The finding raises concerns because depression is not uncommon in people with psoriasis, according to the authors of the study in the Feb. 22 issue of theJournal of Investigative Dermatology.

"For many years, the rheumatology and dermatology communities have been trying to understand which patients with psoriasis go on to develop psoriatic arthritis, and how we might detect it earlier in the disease course," senior investigator Dr. Cheryl Barnabe said in a journal news release. She is from the McCaig Institute for Bone and Joint Health and the O'Brien Institute for Public Health at the University of Calgary in Alberta.

While the study found a connection between depression and the development of psoriatic arthritis, it wasn't designed to prove a cause-and-effect relationship.

RELATED: 9 Ways to Manage PsoriaticArthritis Fatigue

Psoriasis is a condition characterized by red, itchy and scaly skin patches. These patches can sometimes be disfiguring. Psoriatic arthritis generally occurs in people with psoriasis, though it can occur on its own, according to the American College of Rheumatology. The condition causes joint pain and swelling, typically in the large joints and fingers and toes. It can cause joint damage, too.

The study authors noted that prior work has linked having a major depressive disorder with a high risk for systemic inflammation. This could explain why depression would bump up the risk for psoriatic arthritis.

To explore the link, the investigators analyzed information on more than 70,000 psoriasis patients in the United Kingdom that had been collected by a primary care database.

Patients were tracked for upwards of 25 years.

The researchers adjusted the data to account for other factors, such as age and drinking habits. Ultimately, they determined that people who had been depressed faced a much higher risk for psoriatic arthritis than those who hadn't been depressed.

"There is a tendency to think of depression as a purely 'psychological' or 'emotional' issue, but it also has physical effects and changes in inflammatory and immune markers have been reported in depressed people," said Dr. Scott Patten, from the O'Brien Institute.

"Depression may be a risk factor for a variety of chronic conditions, and this research is an example of how big data approaches can identify these associations," he said.

Go here to read the rest:

Can Depression Up Odds for Arthritis Linked to Psoriasis? - Everyday Health (blog)

Psoriasis is a lifelong inflammatory skin disease characterized by red, itchy, and scaly patches of skin. Those who suffer from this disease are also at increased risk for many major medical disorders, including psoriatic arthritis, a type of arthritis characterized by psoriasis plus inflammation of and around the joints.

Now a new Canadian study published in the Journal of Investigative Dermatology finds that psoriasis patients who develop depression have a 37 percent greater risk of subsequently developing psoriatic arthritis, compared with patients who do not develop depression.

For many years, the rheumatology and dermatology communities have been trying to understand which patients with psoriasis go on to develop psoriatic arthritis and how we might detect it earlier in the disease course, said lead researcher Cheryl Barnabe, M.D., M.Sc., of the McCaig Institute for Bone and Joint Health and the OBrien Institute for Public Health, Cumming School of Medicine, at the University of Calgary.

Depression is quite common among psoriasis patients. Based on recent laboratory findings showing that major depressive disorder is associated with increased systemic inflammation, the researchers hypothesized that psoriasis patients who develop depression may be at increased risk of developing psoriatic arthritis.

There is a tendency to think of depression as a purely psychological or emotional issue, but it also has physical effects and changes in inflammatory and immune markers have been reported in depressed people, commented Scott Patten, M.D., Ph.D., the OBrien Institute for Public Health, Hotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education, Cumming School of Medicine.

Depression may be a risk factor for a variety of chronic conditions and this research is an example of how big data approaches can identify these associations.

The researchers evaluated data from primary care medical records in the United Kingdom to find over 70,000 patients with a new diagnosis of psoriasis. Then they identified the patients who subsequently developed depression and those who developed psoriatic arthritis. Patients were followed for up to 25 years or until they developed psoriatic arthritis.

Their findings show that patients with psoriasis who developed major depressive disorder were at 37 percent greater risk of subsequently developing psoriatic arthritis compared with patients who did not develop depression, even after accounting for numerous other factors such as age and use of alcohol.

The research emphasizes the need for physicians who treat patients with psoriasis to actively identify and address depression. This could include rapid, effective treatment of psoriasis and psychosocial management of the cosmetic burden of psoriasis.

The findings also draw into question the biological mechanisms by which depression increases the risk for psoriatic arthritis. These mechanisms may include altered systemic inflammation as a consequence of depression, or even the role of lifestyle behaviors such as physical activity or nutrition, which are typically worsened by depression, and which may place an individual at risk for psoriatic arthritis.

It is evident to physicians who treat patients with psoriasis, that there is a significant psychological and social burden associated with this disease, which is reflected in an increase in the rates of depression, said Laurie Parsons, M.D., of the Cumming School of Medicine.

This study brings us a little closer to understanding the role of chronic inflammation as a systemic player in both the physical and psychological manifestations of psoriasis and underscores the need for closer attention to symptoms of depression in this group of patients.

Source: Elsevier Health Sciences

APA Reference Pedersen, T. (2017). Depression in Psoriasis Patients Ups Risk of Arthritis. Psych Central. Retrieved on February 24, 2017, from https://psychcentral.com/news/2017/02/23/depression-in-psoriasis-patients-ups-risk-of-arthritis/116785.html

Continued here:

Depression in Psoriasis Patients Ups Risk of Arthritis - PsychCentral.com

NEW YORK, Feb. 21, 2017 /PRNewswire/ -- Provides understanding and access to the psoriasis partnering deals and agreements entered into by the worlds leading healthcare companies.

Read the full report: http://www.reportlinker.com/p03605692-summary/view-report.html

Description The Global Psoriasis Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.

- Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type

The report provides understanding and access to the partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.

This data driven report contains multiple links to online copies of actual deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of partnering trends.

Chapter 1 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 2 provides a review of the top 10 most active companies in the therapy area, including a comprehensive listing of the deals announced by each company.

Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

Chapter 4 provides a listing of partnering deals where a contract document is available alongside the deal record.

Chapters 5 and 6 provide a summary of M&A deals since 2010 where the acquired company is active in the therapy area of interest.

Chapters 7 and 8 provide a summary of financings since 2010 where the financed company is active in the therapy area of interest.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products in the therapy area.

Read the full report: http://www.reportlinker.com/p03605692-summary/view-report.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-psoriasis-partnering-2010-to-2017-300411256.html

See original here:

Global Psoriasis Partnering 2010 to 2017 - Yahoo Finance

Approximately 1.8 million people in the UK suffer with psoriasis, a chronic autoimmune skin disease. Psoriasis commonly presents in the mid 30s - but it can occur at any age.

Psoriasis is a common skin condition that causes red patches of inflamed skin with silvery-white scales, often on the elbows and knees but may occur anywhere on the body. It is often genetic and is not contagious.

ADVERTISEMENT - CONTINUE READING BELOW

Skin turnover is accelerated in those suffering from psoriasis, which causes accumulation of cells on the skin surface and leads to scaling. Psoriasis triggers include: stress, cold, dry weather and lack of adequate sun exposure, recent infection such as strep throat and upper respiratory infections, dry skin and injury to the skin such as cuts, burns, and insect bites. Certain medications can induce a psoriasis flare including anti-malarials, beta-blockers, and lithium. Smoking and excessive alcohol consumption may also exacerbate the condition.

Psoriasis can have a significant impact on the quality of life - with confidence, self-esteem and mood often being affected.

Related Article

10 body checks every woman should be doing

Whilst frustratingly there is currently no cure for psoriasis, there are a multitude of treatment options and lifestyle changes to help manage the condition to a certain degree.

We spoke to Dr Alexis Granite, Consultant Dermatologist at the Cadogan Clinic for her expert tips to help deal with psoriasis...

"The first step in managing psoriasis is to visit a dermatologist. Whilst psoriasis is not curable, there are a multitude of treatment options to help control the disease and improve symptoms. Topical steroids, UV therapy and the newer biologics such as Enbrel are examples of some of the therapies available."

ADVERTISEMENT - CONTINUE READING BELOW

"Alcohol or acid-based ingredients (glycolic, salicylic and lactic acid) which can be found in soaps, moisturisers and deodorants, can cause irritation and inflammation."

Getty RUTH JENKINSON

"Keeping a daily diary can helpful in monitoring psoriasis flare-ups. Stress levels, diet, exercise, skin products, medications, exposure to sunlight, and sleep and hydration levels may all play a role. Reviewing a daily diary with your skin specialist may help you better understand and manage the condition."

"Stress is a common trigger for psoriasis. Meditating, yoga, acupuncture and exercise are all effective ways to help reduce stress. Also try to ensure you are getting adequate sleep."

"A well-rounded diet including fruits, vegetables, whole grains, fish and monounsaturated fats may help reduce psoriasis flare-ups. For some patients supplements containing omega 3 fatty acids such as fish oil and flaxseed may also be helpful, but it is advisable to speak with a medical professional before introducing nutritional supplements into your diet."

Related Article

5 hidden links between illnesses you should be aware of

"Both smoking and excessive drinking may make psoriasis significantly worse."

"Applying emollients regularly helps prevent new psoriatic plaques forming and may reduce reduce itching."

"UV exposure helps reduce psoriasis symptoms, but over-exposure can have a detrimental effect on the skin and increases the risk of skin cancer. Always use sun cream to protect your skin and talk to your healthcare professional about the possibility of in-office or home UV treatment."

Link:

8 ways to manage psoriasis - Netdoctor

If you have psoriasis, you already know that smart lifestyle strategies(such as managing stress, not using harsh soaps, and avoiding certain foods)may help keep symptoms at bay. But one of the most important things you can do to keep the skin condition under control might be to shed extra pounds. Here, five reasons why it's so crucial for psoriasis patients to watch their weight.

Psoriasis is an autoimmune disease, which means the immune system attacks a part of the body (in this case, the skin). The result is raised red, white, or silvery patches on the skin, as well as other possible symptoms such as itching, nail disfigurement, or dry, cracked skin. Psoriasis is a chronic condition, meaning you have it for your entire lifebut weight loss may alleviate some of the symptoms.

"Studies show that diet and exercise canreduce symptoms of psoriasis," says Debra Jaliman, MD, a dermatologist based in New York City.In a recent Danish study published inAmerican Journal of Clinical Nutrition, obese psoriasis participants who lost 10% to 15% of their body weight showed significant improvement in symptoms. What's more, the improvement was long-lasting: a year after the study ended, the participants who lost at least 22 pounds from their start weightcontinued to experience improved quality of life.

RELATED: Kim Kardashian Says Her Psoriasis Is 'Part of Who I Am'

About 10% to 30% of psoriasis patients eventually develop psoriatic arthritis, an autoimmune disease that causes painful, swollen joints. But overweight or obese psoriasis patients may be particularly at risk.In a study published in the journalAnnals of the Rheumatic Diseases, researchersfound a link between obesityand increased chance of developing the condition. The study looked at data collectedovera 15-year period of more than 75,000 people in the UK, and found that psoriatic arthritis incidence rates increased along with BMI.

If you're a psoriasis patient who also has psoriatic arthritis, extraweight can strainyour joints, which may aggravate symptoms.Psoriatic arthritis can affect both smaller joints (think: fingers, toes, wrists) as well aslarge, weight-bearing ones like your kneesand added pounds can put unnecessary pressure on them, making symptoms worse.

"No matter what type of arthritis you have, weight is particularly bad for weight-bearing joints, the hips and knees in particular," says James R. ODell, MD, chief of rheumatology at the University of Nebraska Medical Center in Omaha.

Research appears to backthis up:In 2014, Canadian researchers found that obese psoriatic arthritis patients were less likely to achieve a state of remission than those with lower BMIs.

RELATED: 9 Things People With Psoriatic Arthritis Want You to Know

One reasonwhy obese psoriatic arthritis patients may be less likely to achieve remission? Overweight and obese people dont always respond as well to medications used to treat the disease, according to the Arthritis Foundation.

"You have this perfect storm," says Dr. ODell. "Youre more likely to have problems and to have less response to medication."

Losing weight may help medications work more effectively for both psoriatic arthritis and psoriasis.In a 2014 study of obesepsoriasispatients, researchers found that losing weight helped increase the efficacy of biologic drugtreatments.

RELATED: The 12 Best and Worst Foods for Psoriasis

As an added incentive to slim down, losing weight can also reduce your odds of heart disease, diabetes, and strokeconditions that both psoriasis and psoriatic arthritis patients have an elevated risk of developing.

Dr. ODell explains that he encourages all of his patients to get to (and maintain) a healthy body weight. But this isespecially true for those with conditions like psoriatic arthritis and psoriasis.

For them, "weight loss is doubly important," he says."I would say that to about anybody, [but] sometimes people need another reason or an over-and-above reason [to lose weight]."

Continue reading here:

Why Your Weight Matters If You Have Psoriasis - Health.com

Anyone who has psoriasis knows just how uncomfortable it can be. The skin condition, which is actually an autoimmune disease, occurs when skin cells grow and appear on the outer surface of the skin at an accelerated rate. The result? Raised patches of dry red, white, or silvery skin that can feel itchy or even painful.

What most people dont realize is that there are five different forms of the chronic disease, the most common of which is called plaque psoriasis. But what actually causes the uncomfortable condition? While its not entirely clear, its possible that a family history of the disease, as well as lifestyle factors like smoking and obesity, can raise ones risk of psoriasis.

While you may not be able to do anything about your familys genetics, you can certainly take smart steps to stay healthy and lower your risk of psoriasis. For one, ditch your cigarette habit stat. Next, eat the right kinds of foods to keep your body at a healthy weight.

RELATED: Can a Healthy Diet Help Psoriasis?

Not sure which foods will best serve you (pun intended)? Weve got you covered. In this video, we show you the best and worst foods to eat if you have psoriasis.

From fish thats filled with healthy omega-3 fatty acids (like salmon, mackerel, and sardines) to fiber-rich whole grains and antioxidant-heavy blueberries, were highlighting the foods you should put on your plate, plus ones to leave behind at the grocery store, if you have psoriasis.

See original here:

The Best and Worst Foods for Psoriasis - Psoriasis - Health.com Video - Health.com

Secukinumab does not increase IBD incidence in patients with psoriasis, spondyloarthropathies Healio Reports of Crohn's disease and ulcerative colitis among patients with psoriasis, psoriatic arthritis or ankylosing spondylitis treated with secukinumab were infrequent and consistent with earlier findings, according to data presented at the American ...

Read the original post:

Secukinumab does not increase IBD incidence in patients with psoriasis, spondyloarthropathies - Healio

The global psoriasis drugs market is anticipated to witness a high growth during 2016-2022

This report provides a detailed analysis of the current and future market scenario of the global psoriasis drugs market. The report provides insight about the major drivers and challenges, along with the latest innovations in this industry. In addition, the report also highlights various opportunities available for growth of the global psoriasis drugs market.

The global psoriasis drugs market has been segmented on the basis of type of drug molecule into biologics drugs and small molecule/chemical drugs. Biologics are gaining popularity due to the high efficacy and specificity of these drugs for the treatment of various types of psoriasis. Moreover, the increasing awareness about these drugs among people is also helping its market to grow all across the globe.

Furthermore, the global psoriasis drugs market has also been segmented on the basis of their route of administration. According to the report, the psoriasis drugs can be administered by topical route as well as systemic route. Systemic route of administration is expected to witness a high growth owing to its high efficacy. Similarly, the market has been segmented on the basis of mechanism of action of the drug into TNF inhibitors, interleukin blockers, and others. Interleukin blockers are gaining high popularity amongst all classes of drugs.

Market Dynamics

Drivers

Challenges

Opportunities

Companies Mentioned

For more information about this report visit http://www.researchandmarkets.com/research/wszhk3/global_psoriasis

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-psoriasis-drugs-market-outlook-2022---research-and-markets-300411639.html

SOURCE Research and Markets

http://www.researchandmarkets.com

More here:

Global Psoriasis Drugs Market Outlook 2022 - Research and Markets - PR Newswire (press release)

February 22, 2017

Psoriasis is a lifelong disease that is associated with significant cosmetic and physical disability and puts patients at increased risk for many major medical disorders. A multidisciplinary team of researchers at the University of Calgary, Canada, have found that psoriasis patients who developed depression were at a 37% greater risk of subsequently developing psoriatic arthritis, compared with psoriasis patients who did not develop depression. Their findings are published in the Journal of Investigative Dermatology.

Psoriasis is a long-lasting inflammatory skin disease characterized by red, itchy, and scaly patches of skin. Approximately 8.5% of psoriasis patients have psoriatic arthritis, which is characterized by psoriasis plus inflammation of and around the joints.

"For many years, the rheumatology and dermatology communities have been trying to understand which patients with psoriasis go on to develop psoriatic arthritis and how we might detect it earlier in the disease course," explained senior investigator Cheryl Barnabe, MD, MSc, of the McCaig Institute for Bone and Joint Health and the O'Brien Institute for Public Health, Cumming School of Medicine, at the University of Calgary, Alberta, Canada.

Depression is common among patients with psoriasis. Based on recent laboratory work demonstrating that major depressive disorder is associated with increased systemic inflammation, the team of researchers hypothesized that psoriasis patients who develop depression are at increased risk of subsequently developing psoriatic arthritis.

Investigators used The Health Improvement Network (THIN), a primary care medical records database in the United Kingdom, to identify over 70,000 patients with a new diagnosis of psoriasis. Through follow-up records, they identified individuals who subsequently developed depression and those who developed psoriatic arthritis. Patients were followed for up to 25 years or until they developed psoriatic arthritis.

Statistical analysis showed that patients with psoriasis who developed major depressive disorder were at 37% greater risk of subsequently developing psoriatic arthritis compared with patients who did not develop depression, even after accounting for numerous other factors such as age and use of alcohol.

The study highlights the need for physicians to manage patients with psoriasis to identify and address depression. This could include rapid, effective treatment of psoriasis and psychosocial management of the cosmetic burden of psoriasis. The study also draws into question the biological mechanisms by which depression increases the risk for developing psoriatic arthritis. These mechanisms may include altered systemic inflammation as a consequence of depression, or even the role of lifestyle behaviors such as physical activity or nutrition, which are typically worsened by depression, and which may place an individual at risk for psoriatic arthritis.

"There is a tendency to think of depression as a purely 'psychological' or 'emotional' issue, but it also has physical effects and changes in inflammatory and immune markers have been reported in depressed people," commented Scott Patten, MD, PhD, the O'Brien Institute for Public Health, Hotchkiss Brain Institute and Mathison Centre for Mental Health Research and Education, Cumming School of Medicine. "Depression may be a risk factor for a variety of chronic conditions and this research is an example of how big data approaches can identify these associations."

Laurie Parsons, MD, of the Cumming School of Medicine, added: "It is evident to physicians who treat patients with psoriasis, that there is a significant psychological and social burden associated with this disease, which is reflected in an increase in the rates of depression. This study brings us a little closer to understanding the role of chronic inflammation as a systemic player in both the physical and psychological manifestations of psoriasis and underscores the need for closer attention to symptoms of depression in this group of patients."

"This study raises important questions on the role of systemic inflammation, which is also elevated in depression, in driving a disease phenotype, which needs to be confirmed in clinical cohorts," concluded Dr Barnabe.

Explore further: Higher risk for depression with psoriasis

More information: "Depression Is Associated with an Increased Risk of Psoriatic Arthritis among Patients with Psoriasis: A Population-Based Study," by Ryan T. Lewinson, PhD, Isabelle A. Vallerand, PhD, Mark W. Lowerison, MSc, Laurie M. Parsons, MD, Alexandra D. Frolkis, PhD, Gilaad G. Kaplan, MD, MPH, Andrew G.M. Bulloch, PhD, Mark G. Swain, MD, MSc, Scott B. Patten, MD, PhD, and Cheryl Barnabe, MD, MSc, Journal of Investigative Dermatology, volume 137, issue 4 (April 2017) dx.doi.org/10.1016/j.jid.2016.11.032

(HealthDay)There is an increased risk of depression among women with psoriasis, according to a study published online July 17 in the British Journal of Dermatology.

(HealthDay)Gastric bypass, but not gastric banding, is associated with reduced risk of psoriasis, progression to severe psoriasis, and psoriatic arthritis, according to a study published online Dec. 21 in JAMA Surgery.

(HealthDay)The incidence of psoriatic arthritis (PsA) is 2.7 cases per 100 psoriasis patients, with risk factors including severe psoriasis phenotype and low level of education, according to a study published in the April ...

The chronic inflammatory skin condition psoriasis was associated with the risk of major depression, although the risk was unrelated to the severity of the disorder, according to an article published online by JAMA Dermatology.

(HealthDay)Patients with psoriasis are at higher risk of developing arrhythmia, even after controlling for other risk factors, according to a study published in the September issue of the Journal of the American Academy ...

Those experiencing psoriasis, psoriatic arthritis, and rheumatoid arthritis are at higher risk for major adverse cardiovascular events (MACE) and cardiovascular death, according to a multi-institutional study led byPenn ...

A research team led by scientists from Brigham and Women's Hospital (BWH) has carefully scrutinized the immune cells from patients with rheumatoid arthritis, revealing a striking new subset of T-cells that collaborate with ...

Combining a drug for rheumatoid arthritis with one that targets the chikungunya virus can eliminate the signs of chikungunya arthritis in mice in the disease's earliest stage, according to researchers at Washington University ...

About one million Americans each year undergo total knee or hip replacements, but complications bring as many as 1 in 12 back to the hospital and result in higher use of post-acute services within 90 days.

Using a novel approach for imaging the movement of immune cells in living animals, researchers from the Massachusetts General Hospital (MGH) Center for Immunology and Inflammatory Diseases (CIID) have identified what appear ...

Older adults who suffer from arthritis need to keep moving to be functionally independent. But in an examination of a goal that is daunting for most of this aging population, a new Northwestern Medicine study found that performing ...

(HealthDay)Everybody believes running can leave you sore and swollen, right? Well, a new study suggests running might actually reduce inflammation in joints.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Visit link:

Depression puts psoriasis patients at significantly greater risk of psoriatic arthritis - Medical Xpress

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has analysts on the fence after clearing a big hurdle: a big FDA win for its psoriasis drug brodalumab (brand name Siliq). Nonetheless,perspectives vary even across the middle of the road. There are cases made for a greater level of warinesson the risk vs. reward prospects facing Valeant, just as there are those that see the tides could turn over to confidence at any moment.

From the standpoint of Canaccord analyst Neil Maruoka, while FDA approval for the biotech giants psoriasis drug is positive, the drug that boasts a competitive efficacy profile without being contraindicated in patients also stands a risk of limited market opportunity. Why? One predominant reason: The black box warning with restrictive labeling for suicidality.

Therefore, the analyst reiterates a Hold rating on VRX with a price target of $19, which represents a 19% increase from where the shares last closed.

As we had expected following the 14-4 positive vote from the FDA Advisory Committee in July, the FDA has approved Valeants brodalumab [] However, due to concerns about suicidality associated with brodalumab, the labeling will include a black box warning and the drug will only be available through a Risk Evaluation and Mitigation Strategy (REMS) program. While restrictive labeling was expected, we believe that the boxed warning and REMS requirement are likely to limit the potential for the drug. Nonetheless, we expect that brodalumab will eventually become a modest growth driver within Valeants dermatology franchise. [] Given Valeants elevated leverage, lower growth, and higher risk profile, we believe that a discount to the specialty pharma peer group is warranted, Maruoka opines.

However, even amid lingering safety concerns, the analyst ultimately recognizes that the drugs strong efficacy hints at potential. Looking ahead, Maruoka predicts the drugs peak sales could circle $250 million and [] will eventually become a revenue driver for Valeant following its expected launch in the second half of the year.

As usual, we recommend taking analyst notes with a grain of salt. According to TipRanks, Neil Maruoka is ranked #4,289 out of 4,459 analysts. Maruoka has a 35% success rate and forfeits 7.6% in his yearly returns. When suggesting VRX, Maruoka loses 29.8% in average profits on the stock.

After Siliq won by a significant margin in a positive advisory panel vote, Rodman & Renshaw analyst Ram Selvaraju believes the drugs approval was widely anticipated, as well as was the black box warning for suicide ideation. Yet, the analyst deems the psoriasis drug vastly undervalued.

For now, though optimistic, Selvaraju remains sidelined on VRXs overall unsettled picture, reiterating a Neutral rating on shares of VRX with a $23 price target, which represents a 44% increase from where the stock is currently trading.

However, we believe that the market overall continues to underrate Siliq and its potential in the psoriasis domain, as the prevailing opinion appears to be that the drug is lagging agents like Stelara (ustekinumab), sold by Johnson & Johnson (JNJ; not rated), Cosentyx (secukinumab), from Novartis AG (NVS; not rated), and Taltz (ixekizumab), from Eli Lilly & Co. (LLY; not rated), while the safety profile of the drug may deter broader use. However, we would point investors to the extremely low incidence of suicide in the brodalumab pivotal trialssix such cases occurred and the fact that patients suffering from psoriasis are known to suffer from heightened depression anyway. Furthermore, we believe that there is a case to be made for brodalumab as a best-in-class drug from an efficacy standpoint, since it handily beat Stelara in a head-to-head setting, Selvaraju asserts, also highlighting recent asset sales as another advantage weighing in Valeants favor.

Though presently the analyst veers to the side of caution, he notes that with the encouraging FDA green light for Siliqu, should the biotech giant turn over a fourth-quarter beat with better guidance for 2017, he could very well see fit to shift to a bullish perspective.

According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, Ram Selvaraju is ranked #4,144 out of 4,459 analysts. Selvaraju has a 38% success rate and faces a loss of 2.8% in his annual returns. However, when recommending VRX, Selvaraju gains 9.7% in average profits on the stock.

TipRanks analytics demonstrate VRX as a Hold. Out of 10 analysts polled by TipRanks in the last 3 months, 10% are bearish on the stock, 60% remain sidelined, and 30% are bearish on the stock. With a return potential of nearly 6%, the stocks consensus target price stands at $16.78.

Excerpt from:

Valeant Pharmaceuticals Intl Inc (VRX): Will Psoriasis Drug Siliq Turn The Tide For The Giant? - Smarter Analyst

A new drug to treat moderate-to-severe plaque psoriasis carries a black box warning that suicidal ideas and behavior, including completed suicides, have occurred in patients during the drugs clinical trials.

While FDA recently approved Siliq (Valeant Pharmaceuticals), the agency said the drug is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Siliq REMS Program. Prescribers must be certified with the program and counsel patients about this risk. Pharmacies must also be certified with the program and can only dispense Siliq to patients who are authorized to receive it.

Related:Clear skin within reach for psoriasis patients

In addiiton, patients must sign a Patient-Prescriber Agreement Form and be made aware of the need to seek medical attention should they experience new or worsening suicidal thoughts or behavior, feelings of depression, anxiety or other mood changes.

Valeant plans to start marketing the drug in the second half of 2017.

Siliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected) or phototherapy (ultraviolet light treatment) and have failed to respond, or have stopped responding to other systemic therapies.

Related:6 facts to know about the new psoriasis drug

"Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and todays approval provides patients with another treatment option for their psoriasis," said Julie Beitz, MD, director of the Office of Drug Evaluation III in the FDAs Center for Drug Evaluation and Research, in a FDA statement. "Patients and their health care providers should discuss the benefits and risks of Siliq before considering treatment."

Siliqs safety and efficacy were established in 3 randomized, placebo-controlled clinical trials with a total of 4,373 adult participants with moderate-to-severe plaque psoriasis who were candidates for systemic therapy or phototherapy. More patients treated with Siliq compared to placebo had skin that was clear or almost clear.

The most common adverse reactions reported with the use of Siliq include joint pain (arthralgia), headache, fatigue, diarrhea, throat pain (oropharyngeal pain), nausea, muscle pain (myalgia), injection site reactions, influenza, low white blood cell count (neutropenia) and fungal (tinea) infections.

Read more:New biosimilar for RA to save millions

Go here to read the rest:

Psoriasis drug approved with boxed warning - ModernMedicine

There was a significant difference in thickness of the granular layer in patients with palmar psoriasis vs. those with hand eczema, according to study results recently published in the Journal of the American Academy of Dermatology.

Researchers conducted a retrospective analysis of hematoxylin-eosinstained biopsies of 96 patients who presented at an outpatient clinic at Hallym University Sacred Heart Hospital, Anyang, Republic of Korea. The patients were diagnosed with palmar psoriasis, hand eczema or hyperkeratotic hand dermatitis.

The patients were categorized into four cohorts: Palmar psoriasis (n=16; group A); hand eczema without atopic dermatitis or nummular dermatitis (n = 41; group B); hand eczema with atopic dermatitis or nummular dermatitis (n = 14; group C); or hyperkeratotic hand dermatitis (n = 25; group D).

Aa greater proportion of patients in the palmar psoriasis cohort (group A) experienced loss of granular layer (62.5%) compared with group B (24.4%; P = .047) and group C (0%; P = .002).

The proportion of patients experiencing psoriasiform epidermal hyperplasia were 36.6% in group B, 35.7% in group C and 72% in group D. The diagnosis favored the hyperkaratotis hand dermatitis cohort (group D) over group B (P = .01) and group C (P = .043).

There were no significant histologic differences between [palmar psoriasis] and [hyperkeratotic hand dermatitis], the researchers concluded. Most of the characteristic histologic features of psoriasis did not help in the differential diagnosis. Further studies involving the use of other useful diagnostic tools such as immunohistochemical staining should be performed. by Bruce Thiel

Disclosure: The researchers report no relevant financial disclosures.

Read more:

Granular layer thickness differed in palmar psoriasis and hand eczema - Healio

Back to Browse Journals Psoriasis: Targets and Therapy Volume 7

Marina Agozzino,1 Cecilia Noal,2 Francesco Lacarrubba,3 Marco Ardig4

1Dermatology Unit, Second University of Naples, Naples, 2Dermatology Unit, University of Trieste, Trieste, 3Dermatology Clinic, University of Catania, Catania, 4Clinical Dermatology Department, San Gallicano Dermatological Institute, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy

Abstract: Reflectance confocal microscopy (RCM) evaluation of inflammatory skin diseases represents a relatively new technique that, during the past 5years, has attracted increasing interest, with consequent progressive increment of publications in literature. The success of RCM is directly related to the high need for noninvasive techniques able to both reduce the number of skin biopsies and support clinical diagnosis and patient management. RCM helps to visualize microscopic descriptors of plaque psoriasis (PP) with good reproducibility between observers and a high grade of correspondence with histopathology. Several clinical tests are used for the therapeutic management of PP, but they are limited by subjective interpretation. Skin biopsy presents objective interpretation, but the procedure is invasive and not repeatable. RCM has been used not only for the evaluation of skin cancer or inflammatory skin diseases, but also for monitoring the efficacy of different treatments in PP. In this review, we present some examples of RCM applications in therapeutic psoriasis follow-up.

Keywords: reflectance confocal microscopy, psoriasis noninvasive follow-up, psoriasis monitoring

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

More:

Monitoring treatment response in psoriasis: current perspectives on the clinical utility of reflectance confocal ... - Dove Medical Press

Espedilla: Beating Psoriasis at home (part 3) | SunStar Sun.Star Psoriasis would be a lot worse if you won't kick the habit of smoking. In fact, one study have shown that people who smoked more than a pack a day were twice as likely to have a serious case of psoriasis than those who smoked half a pack or less. Women ...

Read the rest here:

Espedilla: Beating Psoriasis at home (part 3) | SunStar - Sun.Star